Home

Ashley Hall

CIK 1801842 · Chief Development Officer · last filed 2026-03-23

Ashley Hall is a Chief Development Officer who has filed 10 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for GPCR, was dated Mar 23, 2026. Across all open-market trades the lifetime net is −$98.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $8.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$8.23M

Companies

3

Total Filings

10

Lifetime Open-Market Net

-$98.1K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GPCR Chief Development Officer 155,187 $52.58 $8.16M $0 5 2026-03-23
OnKure Therapeutics, Inc. (RPHM) Delisted Chief Development Officer 3,960 $18.20 $72.1K -$98.1K 3 2023-08-29
ESPR Chief Development Officer 22,500 $3.18 $71.5K $0 1 2021-01-29

Recent Filings

10 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-23 GPCR Grant (A) +47,706 $0 EDGAR
2026-03-05 GPCR Mixed −4,836 -$101.5K EDGAR
2025-09-22 GPCR Tax (F) −6,021 -$46.6K EDGAR
2025-03-18 GPCR Grant (A) +51,048 $0 EDGAR
2024-09-20 GPCR Grant (A) +67,290 $0 EDGAR
2023-08-29 OnKure Therapeutics, Inc. (RPHM) Delisted Mixed — -$69.9K EDGAR
2023-08-28 OKUR Notice (144) −15,625 -$98.1K EDGAR
2022-12-13 OnKure Therapeutics, Inc. (RPHM) Delisted Grant (A) — $0 EDGAR
2021-11-15 OnKure Therapeutics, Inc. (RPHM) Delisted Grant (A) +30,000 $0 EDGAR
2021-01-29 ESPR Grant (A) +7,000 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.